K. Bélanger

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Michael Weller, Thierry Gorlia, J. G. Cairncross et al. · Neurology · 2011 · 291 citations · Full text

Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme

Jacob C. Easaw, Warren Mason, James Perry et al. · Current Oncology · 2011 · 105 citations · Full text

Surgical Oncology, Oncologic Imaging, Cancer Management +25

Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

J. Maroun, K. Bélanger, Lesley Seymour et al. · Annals of Oncology · 2006 · 70 citations

National Cancer Institute, Solid Tumors, Medicine +8

Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Carol Townsley, K. Chi, D. Scott Ernst et al. · Journal of Clinical Oncology · 2003 · 37 citations

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94)

S. Gertler, David Macdonald, Michael Goodyear et al. · Annals of Oncology · 2000 · 34 citations · Full text

Glioma, Medicine, Metronomic Therapy +9